Cor Vasa 2020, 62(6):618-623 | DOI: 10.33678/cor.2020.103

(Dapagliflozin and heart failure)

Jindřich Špinar, Lenka Špinarová, Jiří Vítovec

Interní kardioangiologická klinika, Lékařská fakulta Masarykovy univerzity a Fakultní nemocnice u sv. Anny v Brně

Type 2 diabetes mellitus (T2DM) is common in patients with chronic heart failure and is associated with high morbidity and mortality. Significant advances have recently occured in the treatment of T2DM and cardiovascular diseases. Several new glucose lowering drugs have shown either neutral or positive cardiovascular effect especially on hospitalisations, but also on mortality. Some of these drugs have safety characteristics with strong practical implication in heart failure, for example dipeptidyl peptidase-4 inhibitors (DPP-4), glucagon-like peptide-1 receptor agonists (GLP-1) and sodium-glucose co-transporters type 2 inhibitors (SGLT-2). Position paper of the European Society of Cardiology/Heart Failure Association was published in October 2019 and in June 2020. Dapagliflozin as a representative of SGLT2 inhibitors was tested in three big clinical trials DECLARE, DAPA-HF, and DAPA-CKD. We present the main results of these trials, with the main attention of the influence of dapagliflozin on heart failure.

Keywords: Dapagliflozin, Heart failure, Renal functions, SGLT2 inhibitors

Received: November 9, 2020; Accepted: November 15, 2020; Published: December 11, 2020  Show citation